• 1
    Feldman EC, Nelson RW. Canine hyperadrenocorticism (Cushing's syndrome). In: FeldmanEC, NelsonRW, eds. Canine and Feline Endocrinology and Reproduction, 3rd ed. St. Louis, MO: WB Saunders; 2004:253265.
  • 2
    Kintzer PP, Peterson ME. Mitotane (o,p'-DDD) treatment of 200 dogs with pituitary-dependent hyperadrenocorticism. J Vet Intern Med 1991;5:182190.
  • 3
    Neuman HC, Potts GO, Ryan WT, et al. Steroidal heterocycles XIII. 4a,4-epoxy-5a-androst-2-eno(2,3-d)isoxazoles and related compounds (1970). J Med Chem 1970;13:948951.
  • 4
    Neiger R, Ramsey I, O'Connor J, et al. Trilostane treatment of 78 dogs with pituitary-dependent hyperadrenocorticism. Vet Rec 2002;150:799804.
  • 5
    Ruckstuhl NS, Nett CS, Reusch CE. Results of clinical examinations, laboratory tests, and ultrasonography in dogs with pituitary-dependent hyperadrenocorticism treated with trilostane. Am J Vet Res 2002;63:506512.
  • 6
    Braddock JA, Church DB, Robertson ID, et al. Trilostane treatment in dogs with pituitary-dependent hyperadrenocorticism. Aust Vet J 2003;81:600607.
  • 7
    Alenza DP, Arenas C, Lopez ML, et al. Long-term efficacy of trilostane administered twice daily in dogs with pituitary-dependent hyperadrenocorticism. J Am Anim Hosp Assoc 2006;42:269276.
  • 8
    Galac S, Buijtels JJ, Mol JA, et al. Effects of trilostane on the pituitary-adrenocortical and renin-aldosterone axis in dogs with pituitary-dependent hypercortisolism. Vet J 2008;183:7580.
  • 9
    Vaughan MA, Feldman EC, Hoar BR, et al. Evaluation of twice-daily, low-dose trilostane treatment administered orally in dogs with naturally occurring hyperadrenocorticism. J Am Vet Med Assoc 2008;232:13211328.
  • 10
    Ramsey IK. Trilostane in dogs. Vet Clin North Am Small Anim Pract 2010;40:269283.
  • 11
    Barker EN, Campbell S, Tebb AJ, et al. A comparison of the survival times of dogs treated with mitotane or trilostane for pituitary-dependent hyperadrenocorticism. J Vet Intern Med 2005;19:810815.
  • 12
    Clemente M, De Andrés PJ, Arenas C, et al. Comparison of non-selective adrenocorticolysis with mitotane or trilostane for the treatment of dogs with pituitary-dependent hyperadrenocorticism. Vet Rec 2007;161:805809.
  • 13
    Kintzer PP, Peterson ME. Mitotane treatment of 32 dogs with cortisol-secreting adrenocortical neoplasms. J Am Vet Med Assoc 1994;205:460.
  • 14
    Eastwood JM, Elwood CM, Hurley KJ. Trilostane treatment of a dog with functional adrenocortical neoplasia. J Small Anim Pract 2003;44:126131.
  • 15
    Benchekroun G, de Fornel-Thibaud P, Lafarge S, et al. Trilostane therapy for hyperadrenocorticism in three dogs with adrenocortical metastasis. Vet Rec 2008;163:190192.
  • 16
    Machida T, Uchida E, Matsuda K, et al. Aldosterone-, corticosterone- and cortisol-secreting adrenocortical carcinoma in a dog: Case report. J Vet Med Sci 2008;70:317320.
  • 17
    Herrtage ME. Canine hyperadrenocorticism. In: MooneyCT, PetersonME, eds. Manual of Canine and Feline Endocrinology, 3rd ed. Gloucester, UK: British Small Animal Veterinary Association; 2004:162163.
  • 18
    Mueller C, Sieber-Ruckstuhl N, Wenger M. Low-dose dexamethasone test with “inverse” results: A possible new pattern of cortisol response. Vet Rec 2006;159:489491.
  • 19
    Gould SM, Baines EA, Mannion PA, et al. Use of endogenous ACTH concentration and adrenal ultrasonography to distinguish the cause of canine hyperadrenocorticism. J Small Anim Pract 2001;42:113121.
  • 20
    Keller-Wood M. Fast feedback control of canine corticotropin by cortisol. Endocrinology 1990;126:19591966.
  • 21
    Dunn KJ, Herrtage ME, Dunn JK. Use of ACTH stimulation tests to monitor the treatment of canine hyperadrenocorticism. Vet Rec 1995;137:161165.
  • 22
    Dohoo I, Martin W, Stryhm H. Screening and diagnostic tests. In: Dohoo I, Modelling Survival Data, Vol. 19. MartinW, StryhmH, eds. Canada: Veterinary Epidemiological Research, AVC Inc; 2003:409454.
  • 23
    van Sluijs FJ, Sjollema BE, Voorhout G, et al. Results of adrenalectomy in 36 dogs with hyperadrenocorticism caused by adrenocortical tumour. Vet Q 1995;17:113116.
  • 24
    Anderson CR, Birchard SJ, Powers BE, et al. Surgical treatment of adrenocortical tumors: 21 cases (1990–1996). J Am Anim Hosp Assoc 2001;37:9397.
  • 25
    Schwartz P, Kovak JR, Koprowski A, et al. Evaluation of prognostic factors in the surgical treatment of adrenal gland tumors in dogs: 41 cases (1999–2005). J Am Vet Med Assoc 2008;232:7784.
  • 26
    Rijnberk A, Belshaw BE. An alternative protocol for the medical management of canine pituitary-dependent hyperadrenocorticism. Vet Rec 1988;122:486488.
  • 27
    Den Hertog E, Braakman JCA, Teske E, et al. Results of non-selective adrenocorticolysis by o,p'-DDD in 129 dogs with pituitary-dependent hyperadrenocorticism. Vet Rec 1999;144:1217.
  • 28
    Feldman EC, Nelson RW, Feldman MS, Farver TB. Comparison of mitotane treatment for adrenal tumor versus pituitary-dependent hyperadrenocorticism in dogs. J Am Vet Med Assoc 1992;200:16421647.
  • 29
    Scavelli TD, Peterson ME, Matthiesen DT. Results of surgical treatment for hyperadrenocorticism caused by adrenocortical neoplasia in the dog: 25 cases (1980–1984). J Am Vet Med Assoc 1986;189:13601364.
  • 30
    Reusch CE, Feldman EC. Canine hyperadrenocorticism due to adrenocortical neoplasia: Pre-treatment evaluation in 41 dogs. J Vet Intern Med 1991;13:291301.